Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 01:12PM ET
3.85
Dollar change
-0.13
Percentage change
-3.27
%
Index- P/E- EPS (ttm)-2.71 Insider Own18.58% Shs Outstand1.54M Perf Week-2.53%
Market Cap5.93M Forward P/E- EPS next Y-3.43 Insider Trans0.00% Shs Float1.25M Perf Month-1.28%
Income-4.13M PEG- EPS next Q-0.76 Inst Own1.10% Short Float0.18% Perf Quarter12.90%
Sales2.54M P/S2.33 EPS this Y85.00% Inst Trans-29.71% Short Ratio0.39 Perf Half Y-34.64%
Book/sh6.36 P/B0.61 EPS next Y-397.10% ROA-32.65% Short Interest0.00M Perf Year-8.34%
Cash/sh5.83 P/C0.66 EPS next 5Y- ROE-35.27% 52W Range2.55 - 5.97 Perf YTD11.59%
Dividend Est.- P/FCF- EPS past 5Y51.08% ROI-42.21% 52W High-35.51% Beta2.62
Dividend TTM- Quick Ratio11.84 Sales past 5Y544.36% Gross Margin- 52W Low50.98% ATR (14)0.27
Dividend Ex-Date- Current Ratio11.84 EPS Y/Y TTM41.51% Oper. Margin-177.78% RSI (14)45.97 Volatility6.96% 6.11%
Employees4 Debt/Eq0.00 Sales Y/Y TTM48.80% Profit Margin-162.78% Recom3.00 Target Price40.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q22.03% Payout- Rel Volume0.71 Prev Close3.98
Sales Surprise- EPS Surprise- Sales Q/Q37.99% EarningsNov 10 BMO Avg Volume5.65K Price3.85
SMA20-6.28% SMA50-0.07% SMA2001.65% Trades Volume2,404 Change-3.27%
Date Action Analyst Rating Change Price Target Change
Jan-08-20Initiated Maxim Group Buy $2.50
Mar-22-24 08:00AM
07:53AM
Jan-17-24 09:00AM
Nov-10-23 08:43AM
08:35AM
10:00AM Loading…
Oct-18-23 10:00AM
Oct-11-23 09:05AM
Sep-05-23 08:05AM
Aug-11-23 09:25AM
08:24AM
08:05AM
Aug-10-23 05:30PM
Jul-13-23 12:00PM
Jul-05-23 08:45AM
May-15-23 08:08AM
12:30PM Loading…
May-12-23 12:30PM
May-11-23 04:42PM
04:30PM
May-04-23 08:35AM
May-03-23 08:35AM
Apr-11-23 08:30AM
Mar-23-23 07:35AM
Mar-16-23 08:05AM
Jan-17-23 08:05AM
Jan-11-23 01:00PM
Jan-05-23 08:05AM
Dec-15-22 06:05AM
Dec-01-22 05:47AM
Nov-16-22 08:35AM
Nov-12-22 08:04AM
07:05AM Loading…
Nov-10-22 07:05AM
Oct-11-22 08:05AM
Oct-04-22 08:00AM
Sep-07-22 08:05AM
Aug-12-22 08:00AM
Aug-02-22 08:05AM
Jul-07-22 09:00AM
Jun-02-22 02:00PM
08:35AM
May-18-22 08:15AM
May-12-22 04:05PM
Apr-27-22 06:30AM
Mar-23-22 08:30AM
Jan-12-22 10:35AM
Nov-12-21 08:00AM
Nov-04-21 03:01PM
Sep-09-21 08:05AM
Sep-08-21 08:00AM
Aug-13-21 08:05AM
Jul-30-21 11:30AM
Jul-28-21 02:00PM
Jul-27-21 08:27AM
Jul-26-21 07:00AM
May-12-21 07:00AM
May-10-21 08:30AM
Mar-29-21 08:05AM
Mar-17-21 08:00AM
Mar-03-21 08:05AM
Mar-01-21 09:49AM
Feb-16-21 07:30AM
Feb-01-21 09:47AM
Jan-14-21 08:00AM
Jan-05-21 08:05AM
Dec-14-20 11:15AM
Dec-10-20 07:42AM
12:50AM
Dec-09-20 11:35AM
08:35AM
Nov-13-20 08:00AM
Nov-05-20 08:05AM
Sep-09-20 08:35AM
Sep-08-20 09:34AM
Aug-13-20 07:05AM
Jul-30-20 08:05AM
Jul-01-20 08:05AM
Jun-16-20 08:05AM
Jun-08-20 08:35AM
May-19-20 07:35AM
May-14-20 04:05PM
Apr-15-20 08:35AM
Mar-27-20 09:00AM
Feb-27-20 08:00AM
Feb-26-20 08:00AM
Feb-13-20 08:00AM
Feb-11-20 08:05AM
Jan-14-20 08:35AM
Nov-15-19 08:30AM
Oct-29-19 07:05AM
Oct-18-19 11:21AM
Oct-16-19 08:05AM
Oct-08-19 08:30AM
Jul-22-19 08:00AM
Jul-17-19 08:45AM
Jul-05-19 01:19PM
Jun-24-19 09:08AM
Jun-20-19 10:24AM
May-14-19 07:42AM
May-13-19 08:05AM
May-02-19 07:05AM
Apr-01-19 07:30AM
Xenetic Biosciences, Inc. is a biopharmaceutical company engaged in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient's malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.